Literature DB >> 7901166

An avirulent lipophosphoglycan-deficient Leishmania major clone induces CD4+ T cells which protect susceptible BALB/c mice against infection with virulent L. major.

P B Kimsey1, C M Theodos, T K Mitchen, S J Turco, R G Titus.   

Abstract

An avirulent clone of Leishmania major was used to immunize susceptible BALB/c mice against challenge with virulent L. major. By using the immunized animals as a source of cells, CD4+ parasite-specific T-cell lines could be generated in vitro which, when adoptively transferred to naive BALB/c recipients, conferred marked protection against challenge with virulent L. major. Compared with CD4+ parasite-specific T-cell lines generated from nonimmunized BALB/c mice infected with L. major, the protective T-cell lines generated from immunized mice produced substantially less interleukin-4 and substantially more tumor necrosis factor and interleukin-2. Interestingly, the protective CD4+ T cells did not mediate L. major-specific delayed-type hypersensitivity in vivo and proliferated in vitro only in response to living L. major and not to frozen-and-thawed antigen preparations of the parasite. Finally, the avirulent clone of L. major was found to express the major surface glycolipid of L. major, lipophosphoglycan, at a level that was sixfold less than expression of this molecule by virulent L. major. In addition, lipophosphoglycan of the avirulent parasite failed to mature into the larger, or metacyclic, form of the molecule.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 7901166      PMCID: PMC281302          DOI: 10.1128/iai.61.12.5205-5213.1993

Source DB:  PubMed          Journal:  Infect Immun        ISSN: 0019-9567            Impact factor:   3.441


  51 in total

Review 1.  Metacyclogenesis in Leishmania promastigotes.

Authors:  D L Sacks
Journal:  Exp Parasitol       Date:  1989-07       Impact factor: 2.011

2.  The induction of protective immunity to Leishmania major in the BALB/c mouse by interleukin 4 treatment.

Authors:  K C Carter; G Gallagher; A J Baillie; J Alexander
Journal:  Eur J Immunol       Date:  1989-04       Impact factor: 5.532

3.  Diffuse cutaneous leishmaniasis: a disease due to an immunological defect of the host.

Authors:  J Convit; M E Pinardi; A J Rondón
Journal:  Trans R Soc Trop Med Hyg       Date:  1972       Impact factor: 2.184

4.  Immunity to experimental infection with Leishmania major: generation of protective L3T4+ T cell clones recognizing antigen(s) associated with live parasites.

Authors:  I Müller; J A Louis
Journal:  Eur J Immunol       Date:  1989-05       Impact factor: 5.532

Review 5.  The involvement of TNF, IL-1 and IL-6 in the immune response to protozoan parasites.

Authors:  R G Titus; B Sherry; A Cerami
Journal:  Immunol Today       Date:  1991-03

6.  Tumour necrosis factor (TNF-alpha) in leishmaniasis. II. TNF-alpha-induced macrophage leishmanicidal activity is mediated by nitric oxide from L-arginine.

Authors:  F Y Liew; Y Li; S Millott
Journal:  Immunology       Date:  1990-12       Impact factor: 7.397

7.  Role of tumor necrosis factor in macrophage leishmanicidal activity in vitro and resistance to cutaneous leishmaniasis in vivo.

Authors:  C M Theodos; L Povinelli; R Molina; B Sherry; R G Titus
Journal:  Infect Immun       Date:  1991-08       Impact factor: 3.441

8.  Developmental changes in the glycosylated phosphatidylinositols of Leishmania donovani. Characterization of the promastigote and amastigote glycolipids.

Authors:  M J McConville; J M Blackwell
Journal:  J Biol Chem       Date:  1991-08-15       Impact factor: 5.157

9.  Reconstitution of Leishmania immunity in severe combined immunodeficient mice using Th1- and Th2-like cell lines.

Authors:  B J Holaday; M D Sadick; Z E Wang; S L Reiner; F P Heinzel; T G Parslow; R M Locksley
Journal:  J Immunol       Date:  1991-09-01       Impact factor: 5.422

10.  Immunological regulation of experimental cutaneous leishmaniasis. III. Nature and significance of specific suppression of cell-mediated immunity in mice highly susceptible to Leishmania tropica.

Authors:  J G Howard; C Hale; F Y Liew
Journal:  J Exp Med       Date:  1980-09-01       Impact factor: 14.307

View more
  16 in total

1.  Vaccines for leishmaniasis and the implications of their development for American tegumentary leishmaniasis.

Authors:  Beatriz Coutinho De Oliveira; Malcolm S Duthie; Valéria Rêgo Alves Pereira
Journal:  Hum Vaccin Immunother       Date:  2019-11-11       Impact factor: 3.452

2.  Characterization of Leishmania donovani antigens encapsulated in liposomes that induce protective immunity in BALB/c mice.

Authors:  Farhat Afrin; Ravindran Rajesh; Khairul Anam; Meenakshisundram Gopinath; Swati Pal; Nahid Ali
Journal:  Infect Immun       Date:  2002-12       Impact factor: 3.441

3.  Development of a safe live Leishmania vaccine line by gene replacement.

Authors:  R G Titus; F J Gueiros-Filho; L A de Freitas; S M Beverley
Journal:  Proc Natl Acad Sci U S A       Date:  1995-10-24       Impact factor: 11.205

4.  Leishmania pifanoi amastigote antigens protect mice against cutaneous leishmaniasis.

Authors:  L Soong; S M Duboise; P Kima; D McMahon-Pratt
Journal:  Infect Immun       Date:  1995-09       Impact factor: 3.441

5.  Coinjection with CpG-containing immunostimulatory oligodeoxynucleotides reduces the pathogenicity of a live vaccine against cutaneous Leishmaniasis but maintains its potency and durability.

Authors:  Susana Mendez; Khaled Tabbara; Yasmine Belkaid; Sylvie Bertholet; Daniela Verthelyi; Dennis Klinman; Robert A Seder; David L Sacks
Journal:  Infect Immun       Date:  2003-09       Impact factor: 3.441

6.  Live attenuated Leishmania donovani p27 gene knockout parasites are nonpathogenic and elicit long-term protective immunity in BALB/c mice.

Authors:  Ranadhir Dey; Pradeep K Dagur; Angamuthu Selvapandiyan; J Philip McCoy; Poonam Salotra; Robert Duncan; Hira L Nakhasi
Journal:  J Immunol       Date:  2013-01-21       Impact factor: 5.422

7.  Leishmania pifanoi amastigote antigen P-4: epitopes involved in T-cell responsiveness in human cutaneous leishmaniasis.

Authors:  J E Haberer; A M Da-Cruz; L Soong; M P Oliveira-Neto; L Rivas; D McMahon-Pratt; S G Coutinho
Journal:  Infect Immun       Date:  1998-07       Impact factor: 3.441

8.  Therapeutic immunization with radio-attenuated Leishmania parasites through i.m. route revealed protection against the experimental murine visceral leishmaniasis.

Authors:  Sanchita Datta; Madhumita Manna; Supriya Khanra; Moumita Ghosh; Radhaballav Bhar; Anindita Chakraborty; Syamal Roy
Journal:  Parasitol Res       Date:  2012-03-23       Impact factor: 2.383

9.  Leishmania donovani whole cell antigen delivered with adjuvants protects against visceral leishmaniasis in vervet monkeys (Chlorocebus aethiops).

Authors:  Joshua Muli Mutiso; John Chege Macharia; Evans Taracha; Michael Muita Gicheru
Journal:  J Biomed Res       Date:  2012-01

10.  Development of novel prime-boost strategies based on a tri-gene fusion recombinant L. tarentolae vaccine against experimental murine visceral leishmaniasis.

Authors:  Noushin Saljoughian; Tahereh Taheri; Farnaz Zahedifard; Yasaman Taslimi; Fatemeh Doustdari; Azam Bolhassani; Delaram Doroud; Hiva Azizi; Kazem Heidari; Mohammad Vasei; Nabiollah Namvar Asl; Barbara Papadopoulou; Sima Rafati
Journal:  PLoS Negl Trop Dis       Date:  2013-04-18
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.